In vitro and in vivo synergetic radiotherapy with gold nanoparticles and docetaxel for pancreatic cancer

Simple item page
dc.contributor.authorAlhussan, Abdulaziz
dc.contributor.authorJackson, Nolan
dc.contributor.authorChow, Norman
dc.contributor.authorGete, Ermias
dc.contributor.authorWretham, Nicole
dc.contributor.authorDos Santos, Nancy
dc.contributor.authorBeckham, Wayne
dc.contributor.authorDuzenli, Cheryl
dc.contributor.authorChithrani, Devika B.
dc.date.accessioned2024-10-10T17:23:09Z
dc.date.available2024-10-10T17:23:09Z
dc.date.issued2024
dc.description.abstractThis research underscores the potential of combining nanotechnology with conventional therapies in cancer treatment, particularly for challenging cases like pancreatic cancer. We aimed to enhance pancreatic cancer treatment by investigating the synergistic effects of gold nanoparticles (GNPs) and docetaxel (DTX) as potential radiosensitizers in radiotherapy (RT) both in vitro and in vivo, utilizing a MIA PaCa-2 monoculture spheroid model and NRG mice subcutaneously implanted with MIA PaCa-2 cells, respectively. Spheroids were treated with GNPs (7.5 ?g/mL), DTX (100 nM), and 2 Gy of RT using a 6 MV linear accelerator. In parallel, mice received treatments of GNPs (2 mg/kg), DTX (6 mg/kg), and 5 Gy of RT (6 MV linear accelerator). In vitro results showed that though RT and DTX reduced spheroid size and increased DNA DSBs, the triple combination of DTX/RT/GNPs led to a significant 48% (p = 0.05) decrease in spheroid size and a 45% (p = 0.05) increase in DNA DSBs. In vivo results showed a 20% (p = 0.05) reduction in tumor growth 20 days post-treatment with (GNPs/RT/DTX) and an increase in mice median survival. The triple combination exhibited a synergistic effect, enhancing anticancer efficacy beyond individual treatments, and thus could be employed to improve radiotherapy and potentially reduce adverse effects.
dc.description.reviewstatusReviewed
dc.description.scholarlevelFaculty
dc.description.sponsorshipThis work was supported by the Kuwait Foundation for the Advancement of Sciences (KFAS) under project code CB21-63SP-01; the NanoMedicines Innovation Network Strategic Initiative fund (NMIN-SI), a member of the Networks of Centers of Excellence Canada program; the John R. Evans Leaders Fund (JELF) from the Canada Foundation for Innovation (CFI); the British Columbia Knowledge Development Fund (BCKDF); the Discovery Grant from the Natural Sciences and Engineering Research Council of Canada (NSERC); the National Institutes of Health (NIH) of the United States of America under grants code R01CA257241, R01DE028105, R21CA252156, and R01CA274415; and a collaborative health grant from the University of Victoria.
dc.identifier.citationAlhussan, A., Jackson, N., Chow, N., Gete, E., Wretham, N., Dos Santos, N., Beckham, W., Duzenli, C., & Chithrani, D. B. (2024). In vitro and in vivo synergetic radiotherapy with gold nanoparticles and docetaxel for pancreatic cancer. Pharmaceutics, 16(6), Article 6. https://doi.org/10.3390/pharmaceutics16060713
dc.identifier.urihttps://doi.org/10.3390/pharmaceutics16060713
dc.identifier.urihttps://hdl.handle.net/1828/20528
dc.language.isoen
dc.publisherPharmaceutics
dc.rightsAttribution CC BY
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectdocetaxel
dc.subjectgold nanoparticles
dc.subjectin vivo
dc.subjectpancreatic cancer
dc.subjectradiotherapy
dc.titleIn vitro and in vivo synergetic radiotherapy with gold nanoparticles and docetaxel for pancreatic cancer
dc.typeArticle

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
alhussan_abdulaziz_pharmaceutics_2024.pdf
Size:
1.59 MB
Format:
Adobe Portable Document Format
Download

Collections

Faculty Publications (BioMed Central & Faculty of Science)
Faculty Publications (Medical Sciences)
 
University of Victoria Libraries

We acknowledge and respect the Lək̓ʷəŋən (Songhees and Esquimalt) Peoples on whose territory the university stands, and the Lək̓ʷəŋən and W̱SÁNEĆ Peoples whose historical relationships with the land continue to this day.